RxDoctor Payments Data

David Borenstein, MD

Rheumatology · Washington, DCNPI 1366441727

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $7,910 of the $9,626 with a category attached, or 82.2%. Eli Lilly accounts for 89.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $8,841 and has fallen 98.1% since, to $164 in 2025.

$9,626in general payments, 2019–2025

Across 39 payments — averaging $246.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$9K
  • Amgen$270
  • GSK$224
  • Sobi, Inc$164
  • Pfizer$134
  • AstraZeneca$124
  • plus $147 from 4 others

What the payments were for

  • Consulting fees$7,91082%
  • Travel & lodging$8459%
  • Food & beverage$8709%
  • Education$10%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly20$8,563
Amgen(2 entities)5$270
GSK3$224
Sobi, Inc1$164
Pfizer1$134
AstraZeneca1$124
AbbVie2$68
Johnson & Johnson4$64
Merck1$14
Lilly USA, LLC1$1

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,626 in reported general payments places this provider in the 65th percentile of 41 rheumatology providers in District of Columbia.

See all rheumatology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$433,193
Medicare patients
351
Services billed
13,690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab29$260,616
EnbrelEtanercept14$104,647
Cevimeline Hcl12$2,745
Prednisone172$2,419
MethotrexateMethotrexate Sodium52$2,316
Risedronate Sodium18$2,282
Duloxetine Hcl35$2,239
Celecoxib60$2,198
Diflunisal20$1,856
Hydroxychloroquine Sulfate35$1,709
Sulfasalazine DrSulfasalazine25$1,431
Tramadol Hcl ErTramadol Hcl18$1,249
Diclofenac Sodium ErDiclofenac Sodium32$1,179
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$773
Meloxicam80$753

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$270$104,64714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 41 rheumatology providers in District of Columbia.

Other rheumatology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →